Russell Investments Group Ltd. lifted its holdings in Simulations Plus, Inc. (NASDAQ:SLP - Free Report) by 24.9% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 223,832 shares of the technology company's stock after acquiring an additional 44,601 shares during the period. Russell Investments Group Ltd. owned approximately 1.11% of Simulations Plus worth $5,488,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also modified their holdings of SLP. Fifth Third Bancorp grew its stake in shares of Simulations Plus by 33.8% in the first quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company's stock valued at $36,000 after acquiring an additional 375 shares in the last quarter. Johnson Financial Group Inc. bought a new stake in Simulations Plus during the fourth quarter worth about $39,000. Tower Research Capital LLC TRC lifted its position in Simulations Plus by 42.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,575 shares of the technology company's stock worth $72,000 after purchasing an additional 764 shares during the period. US Bancorp DE lifted its position in Simulations Plus by 15.6% during the first quarter. US Bancorp DE now owns 6,576 shares of the technology company's stock worth $161,000 after purchasing an additional 889 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Simulations Plus during the first quarter worth about $210,000. 78.08% of the stock is currently owned by institutional investors and hedge funds.
Simulations Plus Trading Down 1.9%
SLP stock opened at $13.77 on Friday. The stock has a market capitalization of $277.19 million, a P/E ratio of -4.37 and a beta of 0.76. Simulations Plus, Inc. has a 12 month low of $12.39 and a 12 month high of $37.72. The firm has a 50-day moving average price of $15.32 and a 200-day moving average price of $25.00.
Simulations Plus (NASDAQ:SLP - Get Free Report) last posted its earnings results on Monday, July 14th. The technology company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.26 by $0.19. The firm had revenue of $20.36 million during the quarter, compared to analysts' expectations of $22.83 million. Simulations Plus had a negative net margin of 78.63% and a positive return on equity of 11.62%. The business's revenue for the quarter was up 9.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.27 earnings per share. As a group, equities analysts predict that Simulations Plus, Inc. will post 1.09 EPS for the current fiscal year.
Analysts Set New Price Targets
Several research firms recently weighed in on SLP. Stephens cut their price objective on shares of Simulations Plus from $28.00 to $20.00 and set an "overweight" rating for the company in a research report on Tuesday, July 15th. JMP Securities reaffirmed a "market perform" rating on shares of Simulations Plus in a research report on Wednesday, June 18th. Wall Street Zen raised shares of Simulations Plus from a "sell" rating to a "hold" rating in a research report on Monday, April 28th. KeyCorp cut shares of Simulations Plus from an "overweight" rating to a "sector weight" rating in a research report on Tuesday, July 15th. Finally, BTIG Research cut their price objective on shares of Simulations Plus from $41.00 to $25.00 and set a "buy" rating for the company in a research report on Monday, July 7th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $26.50.
Get Our Latest Report on SLP
Simulations Plus Company Profile
(
Free Report)
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Featured Stories
Want to see what other hedge funds are holding SLP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Simulations Plus, Inc. (NASDAQ:SLP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Simulations Plus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Simulations Plus wasn't on the list.
While Simulations Plus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.